News

Keep you updated

with the latest info of XtalPi

Laboratoires Pierre Fabre and XtalPi Announce an AI-Driven Collaboration Focused on Drug Discovery
XtalPi Partners with A*STAR under MARVEL-AI to Advance AI-Driven Materials Innovation
XtalPi Receives FDA IND Clearance for Gut-Restricted Pan-TRK Inhibitor
XtalPi Joins HKEX Artificial Intelligence Index Among Top 10 Constituents
XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
XtalPi Open-Sources the First AI Model for Chemical Reaction Yield Quantification
Ailux Presents New Preclinical Data Supporting its Long-Acting IL-4Rα Antibody and Expanding its Bispecific Applications at EADV 2026
XtalPi Debuts Kodexia™, the World’s First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies
XtalPi and Fangda Carbon Deploy Predictive AI to Optimize Cost and Material Efficiency in Graphite Electrode Manufacturing
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain

Search XtalPi

Integrating Multimodal AI with Encoded Medicinal Knowledge and Physics Simulations: A Unified Platform for Accelerated Drug Discovery from Patent Analysis to Potency Validation
AI-Predicted Full-Spectrum UV Correction Factors: An Analyte-Standard-Free Framework for Reaction Yield Quantification
SureRoute: Toward a Hallucination-Free Self-Improving Platform for Retrosynthesis

XtalPi Newsletter